China National Pharmaceutical Group Corporation (600420.SH) subsidiary's amikacin sulfate injection passed consistency evaluation.

Chinatong Finance APP News, China National Pharmaceutical Group Corporation (600420.SH) announced recently that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as China National Rongsheng), has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, approving the production of Amikacin Sulfate Injection through generic drug quality and efficacy consistency evaluation.